Gland Pharma shines despite reporting 15% fall in Q3 consolidated net profit
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Gland Pharma is currently trading at Rs. 1424.30, up by 67.30 points or 4.96% from its previous closing of Rs. 1357.00 on the BSE.
The scrip opened at Rs. 1350.05 and has touched a high and low of Rs. 1431.45 and Rs. 1350.05 respectively. So far 33210 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 3599.00 on 07-Feb-2022 and a 52 week low of Rs. 1309.00 on 24-Jan-2023.
Last one week high and low of the scrip stood at Rs. 1429.90 and Rs. 1309.00 respectively. The current market cap of the company is Rs. 23402.48 crore.
The promoters holding in the company stood at 57.86%, while Institutions and Non-Institutions held 27.79% and 14.34% respectively.
Gland Pharma has reported fall of 16.77% in its net profit at Rs 227.54 crore for third quarter ended December 31, 2022 as compared to Rs 273.38 crore for the corresponding quarter previous year. Total income of the company decreased by 10.96% to Rs 987.41 crore for the quarter under review as compared to Rs 1,108.99 crore for the same quarter in the previous year.
On the consolidated basis, the company has reported fall of 15.05% in its net profit at Rs 231.95 crore for third quarter ended December 31, 2022 as compared to Rs 273.03 crore for the same quarter in the previous year. Total income of the company decreased by 9.85% to Rs 999.80 crore for the quarter under review as compared to Rs 1,108.99 crore for the same quarter in the previous year.
